60 DEGREES PHARMACEUTICALS, INC. (SXTP)
About 60 DEGREES PHARMACEUTICALS, INC.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.0M
- Net income
- -$7.4M
- Total assets
- $5.4M
- Market cap
- $3.8M
- Gross margin
- 22.3%
- Operating margin
- -771.6%
- Net margin
- -732.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.0M
- Cost of revenue
- $781.7K
- Gross profit
- $223.8K
- Operating expenses
- $8.4M
- Operating income
- -$7.8M
- Income tax
- $0
- Net income
- -$7.4M
- EPS (basic)
- $-11.73
- EPS (diluted)
- $-11.73
Balance sheet
- Total assets
- $5.4M
- Current assets
- $4.9M
- Total liabilities
- $2.0M
- Current liabilities
- $1.8M
- Shareholders’ equity
- $3.4M
Cash flow
- Operating cash flow
- -$6.8M
- Investing cash flow
- $254.9K
- Financing cash flow
- $6.4M
- Net cash flow
- -$149.3K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.8M
- EPS (diluted)
- $-11.73
- Shares outstanding
- 2.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 12, 2023
60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Price
- Reported a net loss of $7.4M in FY2025.
- Revenue grew 297% from FY2023 to FY2025.
- Gross margin of 22.3%, net margin -732.8%.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review 60 DEGREES PHARMACEUTICALS, INC..
Write a review
News about 60 DEGREES PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
60 Degrees Pharmaceuticals, Inc.: frequently asked questions
Is 60 Degrees Pharmaceuticals, Inc. an American company?
60 Degrees Pharmaceuticals, Inc. is a US-based company headquartered in Washington, District of Columbia, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is 60 Degrees Pharmaceuticals, Inc. headquartered?
60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, District of Columbia, United States.
Is 60 Degrees Pharmaceuticals, Inc. publicly traded?
Yes — 60 Degrees Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol SXTP on the NASDAQ.
What does 60 Degrees Pharmaceuticals, Inc. do?
60 Degrees Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
